IOP

TRUE Addiction & Behavioral Health Announces Grand Opening

Retrieved on: 
Wednesday, March 20, 2024
Eternity, IOP, Depression, Substance abuse, PHP, Relaxation, Yoga, Dialectical behavior therapy, Behavior, Anxiety, CBT, Drug overdose, Gambling, Cognitive behavioral therapy, Partial, Meditation, DBT, Emotion

Murfreesboro, Tennessee--(Newsfile Corp. - March 20, 2024) - TRUE (Transforming Roots Unto Eternity) Addiction & Behavioral Health proudly announces its grand opening in Murfreesboro, Tennessee for individuals seeking comprehensive addiction and behavioral health services.

Key Points: 
  • Murfreesboro, Tennessee--(Newsfile Corp. - March 20, 2024) - TRUE (Transforming Roots Unto Eternity) Addiction & Behavioral Health proudly announces its grand opening in Murfreesboro, Tennessee for individuals seeking comprehensive addiction and behavioral health services.
  • TRUE offers a spectrum of services addressing substance abuse, mental health disorders, and gambling and process addiction.
  • Dialectical Behavioral Therapy (DBT): Focused on managing emotions and relationships, particularly beneficial for addiction and self-harm.
  • Additionally, TRUE plans to enhance community engagement among the clients with the upcoming opening of a 3,500-square-foot community center this spring.

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
Saturday, April 6, 2024
IOP, Glaucoma, Conditional sentence, Ocular hypertension, Endothelium, Arm, Medicine, Safety, Risk, ASCRS, Patient, Protocol, MD, Genetically modified bacteria, Science, Intraocular pressure, Travoprost, FDA

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
IOP, Gland, Signs, Ciclosporin, Glaucoma, LHT, Wills Eye Hospital, ASCRS, BCEC, Patient, Telecanthus, Meibomian gland dysfunction, Doctor of Philosophy, MD, GEMINI, DED, OMNI, Signs and symptoms, Safety, Poster, Pharmaceutical industry

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points: 
  • OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
  • Lead author: Julio Echegoyen, MD, PhD
    Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
  • The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
  • Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

Connections Wellness Group first outpatient mental health provider to offer Cognia-accredited private school education at no cost to all its patients

Retrieved on: 
Tuesday, April 2, 2024
IOP, Depression, Certification, PHP, Learning, CWG, Education, Patient, School, Accreditation, Mental health, Child, Anxiety, Suicidal ideation, Self-harm, Health, PTSD, Teaching, Nursing

This accreditation allows patients as young as 8 to receive fully transferable school credits while enrolled in a CWG intensive day therapy treatment program to improve their mental health and well-being.

Key Points: 
  • This accreditation allows patients as young as 8 to receive fully transferable school credits while enrolled in a CWG intensive day therapy treatment program to improve their mental health and well-being.
  • We firmly believe a child’s education should not suffer while in behavioral health treatment,” said Christopher Bennett, vice president of education at CWG.
  • “Our intensive day therapy program provides a unique opportunity for patients to receive both necessary mental health treatment and fundamental education.”
    The mission of Connections Wellness Group is to provide life-enriching care that connects patients to long-term wellness.
  • CWG teachers are state-licensed or have advanced degrees, which enhances their ability to provide education to patients in different settings.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
Tuesday, April 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

Burkwood Treatment Center Announces Opening of New Sober Living House

Retrieved on: 
Thursday, March 28, 2024
IOP, Minneapolis–Saint Paul, Environment

HUDSON, Wis., March 28, 2024 (GLOBE NEWSWIRE) -- Burkwood Treatment Center, a top addiction treatment center serving the Twin Cities and beyond, is opening a male-only sober living house for individuals who participate in the afternoon intensive outpatient program (IOP).

Key Points: 
  • HUDSON, Wis., March 28, 2024 (GLOBE NEWSWIRE) -- Burkwood Treatment Center, a top addiction treatment center serving the Twin Cities and beyond, is opening a male-only sober living house for individuals who participate in the afternoon intensive outpatient program (IOP).
  • As an extension of the facility’s comprehensive addiction treatment services, the sober living house will provide a structured and safe environment for individuals who are transitioning from residential care to independent living.
  • Because of this, we are excited to announce the opening of Burkwood Treatment Center’s first sober living house!
  • Residents can benefit from:
    To learn more about the sober living house, rent requirements, and services available at Burkwood Treatment Center, please call (715) 201-2130.

Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology

Retrieved on: 
Wednesday, March 20, 2024
IOP, Ocular hypertension, Professor, NCX, Patient, American Journal, American Journal of Ophthalmology, Glaucoma, Vision science, Intraocular pressure, Pharmaceutical industry

Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025

Key Points: 
  • Topline results from second Phase 3 trial of NCX 470, Denali, expected in H2 2025
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.
  • “The data from the Mont Blanc Phase 3 trial demonstrated the potential of NCX 470 and we look forward to seeing confirmation of this clinical profile in the upcoming results from the ongoing Denali Phase 3 trial, expected in H2 2025.
  • The Mont Blanc publication concludes that “The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with open-angle glaucoma or ocular hypertension at all 6 time points.
  • With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.”

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Retrieved on: 
Wednesday, March 13, 2024
Mont Blanc, IOP, OCT, Whistler, Glaucoma, Ocular hypertension, Fluticasone, Database, Intraocular pressure, NCX, COVID-19, Patient, NDA, BlackRock, Sale, Bausch & Lomb, Therapy, Retina, Allergic conjunctivitis, Safety, Patent, Telecanthus, FDA, Corporation, Food, Pharmaceutical industry

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.

Key Points: 
  • “Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.
  • We are reducing costs, including the size of the organization, and are exploring advancing NCX 1728, through collaborations.
  • In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada.
  • The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Surgery, Health Technology, Health Insurance, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Optical, Retina, IOP, HCPCS, Glaucoma, Ocular hypertension, OAG, OHT, Patient, Corporation, APC, Eye, Surgeon, CPT, Travoprost, GKOS, OPPS, Idose, Medicare, CMS, Government, Intraocular pressure

The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.

Key Points: 
  • The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
  • It is expected to increase patient access in the U.S. and has been published here on the CMS website.
  • “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

Retrieved on: 
Tuesday, April 2, 2024
Health, Clinical Trials, Research, Science, Optical, Biotechnology, IOP, Kiwi (bird), Ocular hypertension, OAG, Glaucoma, Pressure, EVP, OHT, NTG, Patient, Ageing, Hyperaemia, Humour, Latanoprost, ATP, Safety, Pharmaceutical industry

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.

Key Points: 
  • Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.
  • Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.
  • “The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control has been an unachievable goal,” said Thurein Htoo, Chief Executive Officer.
  • “IOP remains the only modifiable risk factor for the treatment of glaucoma, and additional treatments are needed for patients.